MedWatch

ALK reaches important US milestone

The Danish company Alk-Abello has moved one step closer to the US market, as its partner Merck has delivered a registration application to the FDA.

Late last week ALK’s US partner, Merck & Co., sent an application for marketing approval for ALKs drug against grass pollen allergy to the FDA – an extremely important milestone to the Danish company – ALK reveals in a stock market release.

The drug comes in the form of a pill and it is marketed in Europe under the name GRAZAX. The partnership with Merck pertains to the development, registration and commercialization of a large portfolio of pill-based vaccines for the North American markets.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier